Seeking Alpha

Oppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after...

Oppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after positive commentary from investor meetings. Investors are becoming more comfortable with QCOR's perceived risks, the firm says, and any additional negative reports will result in limited downside volatility. Acthar reimbursement rates remain “extremely strong,” the firm adds.
Comments (2)
  • mcINVESTOR
    , contributor
    Comments (24) | Send Message
     
    Thats hilarious!
    19 Sep 2012, 01:38 PM Reply Like
  • SeekingAsp
    , contributor
    Comment (1) | Send Message
     
    I wonder if this firm (the "recommender") will ever recover from this. I see the put series showing 1000 to 20000% gains overnight. I wonder if this will trigger an investigation into all far out Put positions taken yesterday and earlier today.
    19 Sep 2012, 03:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs